Which Antibiotics Are Used to Treat Chlamydia?

Doxycycline, a tetracycline-class antibiotic taken twice daily for seven days, is the recommended first-line treatment for uncomplicated chlamydia in most adolescents and adults. Azithromycin, once favored because it could be given as a single dose, has been downgraded to an alternative after head-to-head studies showed it falls short in certain situations. The picture gets more complicated for pregnant people, newborns, and infections at sites beyond the genitals, where different drugs and dosing schedules apply.

Why Doxycycline Overtook Azithromycin

For years, the single-dose convenience of azithromycin (one gram, taken once) made it the go-to chlamydia treatment. A clinician could hand patients the pills and watch them swallow, eliminating any worry about whether they would finish a week-long course. That logic was sound, but the cure rates told a different story. In a controlled trial where both drugs were given under direct observation, doxycycline cleared urogenital chlamydia in every participant, while azithromycin achieved about a 97 percent cure rate, with treatment failure in roughly 3 percent of cases. The trial could not confirm that azithromycin was as effective as doxycycline.¹

Based on accumulating evidence like this, the 2021 CDC sexually transmitted infections treatment guidelines shifted their recommendation. Doxycycline 100 mg twice daily for seven days is now the preferred regimen for urogenital chlamydia in both men and women. Azithromycin remains an alternative when there is genuine concern about whether a patient will complete the full doxycycline course, such as with some adolescents.²

The Rectal Chlamydia Gap

The advantage of doxycycline becomes far more dramatic for rectal infections, which are common among men who have sex with men and also occur in women. A large randomized trial found that doxycycline cured about 97 percent of asymptomatic rectal chlamydia cases, compared with roughly 76 percent for single-dose azithromycin, a gap of about 20 percentage points.³ A systematic review and meta-analysis pooling multiple studies confirmed that pattern, with doxycycline approaching 100 percent pooled efficacy for rectal chlamydia and azithromycin hovering around 83 percent.⁴

A multicenter observational study in women painted a similar picture. Among women with rectal chlamydia, doxycycline cleared the infection about 96 percent of the time versus about 79 percent for azithromycin. For vaginal infections in the same study, the two drugs performed much closer together, with cure rates above 93 percent for both.⁵ The takeaway is that for any chlamydia infection in the rectum, doxycycline is strongly preferred. The CDC treatment guidelines echo this position explicitly.²

Treatment During Pregnancy

Doxycycline is off the table for pregnant people because tetracyclines can harm developing teeth and bones. That rules out the standard first-line drug and sends clinicians to a different shelf of the pharmacy. The alternatives that have been studied most are azithromycin, amoxicillin, erythromycin, and clindamycin.⁶

In practice, azithromycin (single one-gram dose) and amoxicillin (500 mg three times daily for seven days) are the most commonly prescribed options. A randomized trial comparing the two in pregnant women found similar cure rates, around 58 to 64 percent, with no significant difference in tolerability.⁷ Those numbers look lower than what we see in the general population, partly because pregnancy itself can complicate drug absorption and because follow-up in these trials captured reinfection and redetection too. Erythromycin works but tends to cause enough nausea and vomiting that some women stop taking it before finishing the course. A Cochrane review of trials involving nearly 1,500 pregnant women concluded that amoxicillin was an effective alternative to erythromycin, though none of the trials assessed long-term outcomes for the baby such as reduced eye or lung infections.⁶

What About Newborns?

Babies can pick up chlamydia during birth if the mother has an untreated infection. The two main consequences are chlamydial conjunctivitis (eye infection) and pneumonia. For both, oral erythromycin given over two weeks is the standard treatment. Topical eye drops alone are not enough, because the organism can also be present in the nasopharynx, and a systemic antibiotic is needed to clear it.⁸

A practical complication is that erythromycin does not always work on the first try. Roughly 20 to 30 percent of infants will need a second course because the initial round fails to eradicate the organism.⁸ The other concern is pyloric stenosis, a condition where the muscle at the stomach’s outlet thickens and blocks food from passing through. Both erythromycin and azithromycin carry some risk, especially when given to infants younger than two weeks. Among very young neonates, erythromycin carries a somewhat higher risk than azithromycin, though both are elevated compared to no antibiotic at all.⁹ Pediatricians weigh this risk against the consequences of untreated chlamydial infection, which in an infant’s eyes can lead to scarring and vision loss.

When Chlamydia and Gonorrhea Show Up Together

Co-infection with gonorrhea is common, since the two bacteria share transmission routes and risk factors. Treatment needs to cover both organisms simultaneously. The standard approach pairs a cephalosporin antibiotic for gonorrhea with doxycycline for chlamydia. A randomized trial compared two versions of this pairing: high-dose intravenous ceftriaxone plus doxycycline versus oral cefixime plus doxycycline. Both regimens cured gonorrhea at rates above 95 percent, but the ceftriaxone-doxycycline combination was superior for clearing the dual infection.¹⁰

Because chlamydia is so often found alongside gonorrhea and other bacteria in pelvic inflammatory disease (PID), treating complicated ascending infections requires broad-spectrum coverage rather than a single antibiotic. PID regimens typically combine drugs that hit chlamydia, gonorrhea, and anaerobic bacteria all at once.¹¹

Side Effects and Finishing the Course

One reason azithromycin was popular for so long is the perception that a single pill is easier to tolerate. In reality, the side-effect profiles of the two drugs are fairly similar. An early controlled trial found that about 17 percent of patients on azithromycin and 20 percent of those on doxycycline experienced mild-to-moderate side effects, mostly digestive symptoms like nausea and stomach upset.¹²

The real question with doxycycline is whether people actually finish all 14 pills over seven days. A prospective study of patients prescribed doxycycline for chlamydia in emergency departments and STI clinics found that side effects accounted for nonadherence in only a small fraction, about 2 to 4 percent of patients.¹³ The most common complaint with doxycycline is esophageal irritation if you take the pill without enough water or lie down too soon after. Taking it with food and a full glass of water, and staying upright for at least 30 minutes, helps avoid that. Photosensitivity (sunburn happening faster than expected) is another side effect worth knowing about, especially in summer or for people who spend a lot of time outdoors.

Why Resistance Has Not Become a Crisis (Yet)

With most bacterial infections, antibiotic resistance is the elephant in the room. Chlamydia is unusual in this regard. Despite decades of antibiotic use, researchers have found very few documented cases of clinically significant resistance in human chlamydia strains. Isolates that showed resistance in the lab have generally lost that trait over time or lost viability altogether.¹⁴

That does not mean the organism has no tricks. Chlamydia can enter a dormant state called persistence when it encounters hostile conditions, including antibiotic exposure. In this state, the bacteria stop replicating and become harder to kill, but they are not genetically resistant in the traditional sense. Once the stress is removed, they can wake up and resume their normal infectious cycle.¹⁵ This distinction matters because persistence can explain treatment failure or apparent reinfection even when the antibiotic “should” have worked. The bacteria were not resistant; they were hiding.

There is a cautionary note from the veterinary world. Tetracycline-resistant chlamydia strains have been found in pigs, showing that the organism can acquire resistance genes under sufficient selective pressure.¹⁴ Whether similar resistance could eventually emerge in human populations remains an open question. The heavy and repeated use of antibiotics in clinical settings certainly creates the selective pressure needed, even if it has not produced stable resistance yet.

Treating the Partner, Not Just the Patient

Curing one person’s chlamydia does little good if their sexual partner remains infected and passes it right back. That cycle of reinfection is one of the biggest challenges in chlamydia control. One approach that tries to break it is expedited partner therapy, or EPT, where the clinician gives the diagnosed patient extra medication (or a prescription) to deliver to their partner without the partner needing their own clinic visit. Over 30 states in the U.S. permit EPT for chlamydia, and the practice generally increases the number of partners who get treated.¹⁶

Whether EPT actually reduces reinfection rates has been harder to prove. One urban clinic’s implementation study found that EPT acceptance was linked to lower odds of chlamydial reinfection, but the reduction did not reach statistical significance.¹⁷ The practical barrier is straightforward: not every patient actually hands the medication to their partner. Still, EPT remains a useful tool, particularly for patients whose partners are unlikely to seek care on their own.

The Microbiome Angle

Any antibiotic kills more than its intended target, and chlamydia treatments are no exception. Emerging research has begun looking at what happens to the microbial communities in the vagina and rectum after treatment. A recent study of women in Fiji treated with azithromycin for chlamydia found shifts in the vaginal microbiome, including an increase in bacteria associated with higher risk of STI acquisition and reinfection. Resistance genes to the two main chlamydia-treating drug classes also emerged in the broader microbial community after treatment.¹⁸

This is still early-stage research (the study above is a preprint), but it highlights a potential downside of repeated antibiotic courses for chlamydia. If treatment disrupts the local microbial environment in ways that make reinfection more likely, you can end up on a treadmill of treatment and reinfection. It adds another reason to take prevention seriously, including condom use and partner treatment, rather than relying on repeated antibiotic cures.

The Vaccine Question

The long-term solution to chlamydia may not be better antibiotics but a vaccine that prevents infection in the first place. For decades, a chlamydia vaccine seemed perpetually out of reach, but there has been real progress in recent years. The first vaccine candidate for genital chlamydia entered Phase I clinical trials, with several more candidates in development.¹⁹

Researchers are also exploring newer delivery platforms, including biodegradable nanoparticle systems that could serve as both carrier and immune-booster for chlamydial antigens.²⁰ Separately, computational analyses of chlamydia’s genome have identified new potential drug targets and vaccine candidates among the organism’s essential proteins.²¹ A working vaccine is likely still years away from widespread use, but the pipeline is more active than it has ever been. Given the persistence challenges and the collateral damage antibiotics cause to microbial ecosystems, a preventive approach would represent a genuine shift in how the world manages this infection.

1
PubMed Central. Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection
2
Clinical Infectious Diseases. Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines
3
PubMed. Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis
4
Journal of Antimicrobial Chemotherapy. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis
5
PubMed Central. Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure)
6
PubMed Central. Interventions for treating genital chlamydia trachomatis infection in pregnancy
7
American Journal of Obstetrics and Gynecology. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy
8
PubMed. Neonatal chlamydial infections: prevention and treatment
9
PubMed Central. Treatment of Neonatal Chlamydial Conjunctivitis: A Systematic Review and Meta-analysis
10
PubMed Central. Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection
11
PubMed. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease
12
PubMed. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis
13
PubMed Central. Adherence to doxycycline for uncomplicated genitourinary chlamydia: A prospective observational study
14
PubMed Central. Antibiotic resistance in Chlamydiae
15
Frontiers in Microbiology. Chlamydia Persistence: A Survival Strategy to Evade Antimicrobial Effects in-vitro and in-vivo
16
PubMed Central. Expedited partner therapy for sexually transmitted infections
17
Sexually Transmitted Diseases. Implementation and Effectiveness of an Expedited Partner Therapy Program in an Urban Clinic
18
bioRxiv. Effect of Azithromycin treatment on the microbial composition, functional dynamics and resistomes of endocervical, vaginal and rectal microbiomes of women in Fiji with Chlamydia trachomatis infection
19
PubMed Central. Future prospects for new vaccines against sexually transmitted infections
20
PubMed Central. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles
21
Computers in Biology and Medicine. Chlamydia trachomatis core genome data mining for promising novel drug targets and chimeric vaccine candidates identification